Posts NEWS Mon, 08.08.2022 8th AFNET/EHRA Consensus Conference 2021 Paper published The 8th AFNET/EHRA Consensus Conference Paper 2021 “Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation” has been published: https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euac062/6650662
Posts NEWS Wen, 13.07.2022 Theme booklet of neurology The current issue of “theme booklet of neurology” reports on Atrial Fibrillation NETwork (AFNET), get your access here (german only).
Posts NEWS Thu, 07.07.2022 EAST-AFNET 4 @ ESC 2022 The newest subanalysis of the EAST-AFNET 4 study will be presented at this year’s ESC congress 2022 in Barcelona: Latest science in atrial fibrillationPredictors and mediators of improved outcomes on early rhythm control an analysis of the EAST AFNET – 4 data set.Monday, 29th of August … Read more
Posts NEWS Fri, 29.04.2022 Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control Press release Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control Early rhythm control therapy reduces cardiovascular complications compared to … Read more
The design paper was successfully published in “Frontiers in cardiovascular medicine”. Get access to the paper here.
The latest results of the EAST-AFNET 4 study will be presented at this year’s EHRA congress 2022:
Late Breaking Clinical Trials II
Atrial fibrillation – News on ablation and sex differences
Monday, 4th of April 2022 | 6:15 pm – 7:15 pm (CEST), Room 1
Session chaired by Tatjana Potpara
More information
Early rhythm control is useful in patients with atrial fibrillation regardless of the AF pattern. Patients with first diagnosed atrial fibrillation benefit from early rhythm control therapy comparably to patients with paroxysmal or persistent AF. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Andreas Goette, St. Vincenz Hospital Paderborn, at the American Heart Association (AHA) congress on 14.11.2021 in Boston [1].
Asymptomatic patients with atrial fibrillation (AF) benefit from early rhythm control therapy comparably to symptomatic patients. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Stephan Willems, Asklepios Hospital St. Georg, Hamburg, at the annual congress of the European Society of Cardiology (ESC) on 27.08.2021 [1] and published in the European Heart Journal [2].
The latest results of the EAST – AFNET 4 study will be presented at this year’s ESC Congress 2021 (streamed live):
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
Friday, 27th of August 2021 | 10.30am – 11:15am (CEST)
Presented by Prof. Dr. Stephan Willems
Die neuesten Ergebnisse der EAST-AFNET 4 Studie werden auf dem diesjährigen ESC Congress 2021 als Live-Stream präsentiert:
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
27.08.2021 | 10:30 – 11:15 Uhr (CEST)
Präsentiert von Prof. Dr. Stephan Willems
